Several studies have demonstrated that mutations in RUNX1, NRAS, SETBP1, and ASXL1 are independently associated with a poor prognosis in CMML, while TET2 mutations have been related to favorable outcomes [8,22,23,24]. Here, NRAS is linked to chronic myelomonocytic leukemia.